Patents by Inventor Feifei Cui

Feifei Cui has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-GLYPICAN 3 ANTIBODIES
    Publication number: 20250154280
    Abstract: This disclosure provides anti-GPC3 antibodies, including murine antibodies, humanized antibodies, and those with further optimized CDR sequences. The newly disclosed antibodies exhibited higher cell-based binding efficiency than the leading anti-GPC3 antibody candidate under clinical development.
    Type: Application
    Filed: January 16, 2025
    Publication date: May 15, 2025
    Inventors: Liu YANG, Hao SHEN, Feifei CUI, Lei FANG
  • ANTI-GLYPICAN 3 ANTIBODIES
    Publication number: 20240409663
    Abstract: Provided are anti-GPC3 antibodies, including murine antibodies, humanized antibodies, and those with further optimized CDR sequences. The antibodies exhibited higher cell-based binding efficiency than the leading anti-GPC3 antibody candidate under clinical development.
    Type: Application
    Filed: October 17, 2022
    Publication date: December 12, 2024
    Inventors: Liu YANG, Hao SHEN, Feifei CUI, Lei FANG
  • SINGLE DOMAIN PD-L1 ANTIBODIES
    Publication number: 20240209093
    Abstract: Provided are single domain anti-PD-L1 antibodies and polypeptides, such as bispecific antibodies and chimeric antigen receptors, that include these single domain antibodies. These antibodies, including their humanized counterparts, exhibited superior activities and are suitable for use in various bispecific antibody formats. Methods of using the antibodies or polypeptides for treating and diagnosing diseases such as cancer and infectious diseases are also provided.
    Type: Application
    Filed: April 26, 2022
    Publication date: June 27, 2024
    Inventors: Wenqing JIANG, Yan LIU, Haijuan GU, Feifei CUI, Zhengyi WANG, Bingshi GUO
  • ANTI-PD-L1/ANTI-B7-H3 MULTISPECIFIC ANTIBODIES AND USES THEREOF
    Publication number: 20230192861
    Abstract: The present disclosure provides an anti-PD-L1/anti-B7-H3 multispecific antibody capable to effectively block the interaction between PD-L1 and its receptor PD-1, and suppress the T-cell inhibitory effect of B7-H3 protein. The multispecific antibody may have high binding affinity to both of a PD-L1 protein and a B7-H3 protein.
    Type: Application
    Filed: November 23, 2020
    Publication date: June 22, 2023
    Inventors: Eunsil Sung, Eunyoung Park, Jaehyoung Jeon, Junhyun Jeong, Daehae Song, Sunju Lee, Lei Fang, Wenqing Jiang, Feifei Cui
  • Anti-PD-L1 antibody and IL-7 fusions
    Patent number: 11401331
    Abstract: Provided are fusion molecule having a PD-L1 inhibitor fused to a human IL-7 protein or fragment thereof through a peptide linker. The disclosed fusion molecules exhibited synergistic anti-tumor effects.
    Type: Grant
    Filed: January 25, 2019
    Date of Patent: August 2, 2022
    Assignee: I-Mab Biopharma US Limited
    Inventors: Lei Fang, Feifei Cui, Haijuan Gu, Zhengyi Wang, Bingshi Guo, Jingwu Zang
  • BIFUNCTIONAL MOLECULES WITH IL-7 ACTIVITY
    Publication number: 20220112258
    Abstract: Provided are polypeptides having an antigen-binding unit targeting a tumor antigen and an IL-7 protein or fragment thereof, fused to a Fc fragment. The disclosed polypeptides can be used for treating cancer.
    Type: Application
    Filed: July 27, 2020
    Publication date: April 14, 2022
    Inventors: Feifei Cui, Lei Fang, Yuanyuan Yang, Zhengyi Wang, Bingshi Guo
  • Human PD-L1 antibodies
    Patent number: 11208486
    Abstract: Provided are full human anti-PD-L1 antibodies or fragments thereof. In various examples, the antibodies or fragments thereof include a VH CDR1, a VH CDR2, a VH CDR3, a VL CDR1, a VL CDR2, and a VL CDR3 which are selected from sequence groups of SEQ ID NO: 35-42, SEQ ID NO: 43-51, SEQ ID NO: 52-66, SEQ ID NO: 67-79, SEQ ID NO:80-88 and SEQ ID NO: 89-102, respectively, or variants of each thereof. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer and infectious diseases are also provided.
    Type: Grant
    Filed: April 26, 2020
    Date of Patent: December 28, 2021
    Assignee: I-Mab Biopharma US Limited
    Inventors: Lei Fang, Yuanyuan Yang, Zhengyi Wang, Bingshi Guo, Feifei Cui
  • HUMAN PD-L1 ANTIBODIES
    Publication number: 20210309747
    Abstract: Provided are full human anti-PD-L1 antibodies or fragments thereof. In various examples, the antibodies or fragments thereof include a VH CDR1, a VH CDR2, a VH CDR3, a VL CDR1, a VL CDR2, and a VL CDR3 which are selected from sequence groups of SEQ ID NO: 35-42, SEQ ID NO: 43-51, SEQ ID NO: 52-66, SEQ ID NO: 67-79, SEQ ID NO:80-88 and SEQ ID NO: 89-102, respectively, or variants of each thereof. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer and infectious diseases are also provided.
    Type: Application
    Filed: April 26, 2020
    Publication date: October 7, 2021
    Inventors: Lei Fang, Yuanyuan Yang, Zhengyi Wang, Bingshi Guo, Feifei Cui
  • Antibodies to T cell immunoreceptor with IG and ITIM domains (TIGIT) and uses thereof
    Patent number: 10973853
    Abstract: The present disclosure provides antibodies and fragments thereof having specificity to a human T cell immunoreceptor with Ig and ITIM domains (TIGIT) protein. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer and viral infections are also provided.
    Type: Grant
    Filed: February 11, 2019
    Date of Patent: April 13, 2021
    Assignee: I-Mab Biopharma US Limited
    Inventors: Feifei Cui, Lei Fang, Bingshi Guo, Zhengyi Wang, Jingwu Zang
  • ANTIBODIES TO T CELL IMMUNORECEPTOR WITH IG AND ITIM DOMAINS (TIGIT) AND USES THEREOF
    Publication number: 20210015858
    Abstract: The present disclosure provides antibodies and fragments thereof having specificity to a human T cell immunoreceptor with Ig and ITIM domains (TIGIT) protein. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer and viral infections are also provided.
    Type: Application
    Filed: February 11, 2019
    Publication date: January 21, 2021
    Inventors: Feifei Cui, Lei Fang, Bingshi Guo, Zhengyi Wang, Jingwu Zang
  • ANTI-PD-L1 ANTIBODY AND IL-7 FUSIONS
    Publication number: 20190352405
    Abstract: Provided are fusion molecule having a PD-L1 inhibitor fused to a human IL-7 protein or fragment thereof through a peptide linker. The disclosed fusion molecules exhibited synergistic anti-tumor effects.
    Type: Application
    Filed: January 25, 2019
    Publication date: November 21, 2019
    Inventors: Lei Fang, Feifei Cui, Haijuan Gu, Zhengyi Wang, Bingshi Guo